Literature DB >> 15778493

Resident Th1-like effector memory cells in pulmonary recall responses to Mycobacterium tuberculosis.

Jessica Walrath1, Lynn Zukowski, Adriana Krywiak, Richard F Silver.   

Abstract

We recently described a model of Th1 recall responses based on segmental antigen challenge with purified protein derivative of Mycobacterium tuberculosis (PPD). Bronchoscopic instillation of 0.5 tuberculin units of PPD resulted in localized lymphocytic inflammation in PPD-positive subjects only. Recruited lymphocytes were predominantly CD4+ and were enriched for cells capable of PPD-specific interferon (IFN)-gamma production. In the current study, we investigated the mechanisms by which this localized recall response is mobilized. Bronchoscopic PPD challenge of skin test-positive subjects resulted in the production of CXCR3 ligands IFN-gamma-inducible protein (IP)-10 and monokine induced by IFN-gamma (Mig), but not of CCR5 ligands macrophage inflammatory protein-1alpha and regulated-upon activation, normal T-cell expressed and secreted, whereas skin test-negative subjects produced none of these chemokines. Baseline bronchoalveolar lavage (BAL) cells of skin test-positive subjects produced IP-10 and Mig in response to in vitro stimulation as well. Because IP-10 and Mig are IFN-gamma-inducible chemokines, these findings suggested that chemokine responses to PPD were facilitated by resident memory cells of the lung. Further studies confirmed that baseline BAL lymphocytes of PPD-positive subjects produce IFN-gamma in response to PPD, and that, compared with peripheral blood, BAL cells are preferentially enriched for PPD-specific lymphocytes. This IFN-gamma production is predominantly a function of CD4+ T cells that display the CD45RO+/CCR7- surface phenotype characteristic of effector memory cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15778493      PMCID: PMC2715303          DOI: 10.1165/rcmb.2005-0060OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  29 in total

1.  The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions.

Authors:  S Qin; J B Rottman; P Myers; N Kassam; M Weinblatt; M Loetscher; A E Koch; B Moser; C R Mackay
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

Review 2.  The host immune response to tuberculosis.

Authors:  N W Schluger; W N Rom
Journal:  Am J Respir Crit Care Med       Date:  1998-03       Impact factor: 21.405

Review 3.  Investigative use of bronchoscopy in asthma.

Authors:  N N Jarjour; S P Peters; R Djukanović; W J Calhoun
Journal:  Am J Respir Crit Care Med       Date:  1998-03       Impact factor: 21.405

4.  The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells.

Authors:  A Sauty; M Dziejman; R A Taha; A S Iarossi; K Neote; E A Garcia-Zepeda; Q Hamid; A D Luster
Journal:  J Immunol       Date:  1999-03-15       Impact factor: 5.422

5.  Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol.

Authors:  R Condos; W N Rom; N W Schluger
Journal:  Lancet       Date:  1997-05-24       Impact factor: 79.321

6.  Lymphocyte-dependent inhibition of growth of virulent Mycobacterium tuberculosis H37Rv within human monocytes: requirement for CD4+ T cells in purified protein derivative-positive, but not in purified protein derivative-negative subjects.

Authors:  R F Silver; Q Li; W H Boom; J J Ellner
Journal:  J Immunol       Date:  1998-03-01       Impact factor: 5.422

Review 7.  Management of health care workers after inadvertent exposure to tuberculosis: a guide for the use of preventive therapy.

Authors:  W W Stead
Journal:  Ann Intern Med       Date:  1995-06-15       Impact factor: 25.391

8.  Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection.

Authors:  S E Dorman; S M Holland
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

9.  Enhanced responses to Mycobacterium tuberculosis antigens by human alveolar lymphocytes during active pulmonary tuberculosis.

Authors:  S K Schwander; M Torres; E Sada; C Carranza; E Ramos; M Tary-Lehmann; R S Wallis; J Sierra; E A Rich
Journal:  J Infect Dis       Date:  1998-11       Impact factor: 5.226

10.  Mapping of T cell epitopes of the 30-kDa alpha antigen of Mycobacterium bovis strain bacillus Calmette-Guérin in purified protein derivative (PPD)-positive individuals.

Authors:  R F Silver; R S Wallis; J J Ellner
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

View more
  32 in total

1.  CCL5 participates in early protection against Mycobacterium tuberculosis.

Authors:  Bridget Vesosky; Erin K Rottinghaus; Paul Stromberg; Joanne Turner; Gillian Beamer
Journal:  J Leukoc Biol       Date:  2010-04-06       Impact factor: 4.962

2.  Polyfunctional Mycobacterium tuberculosis-specific effector memory CD4+ T cells at sites of pleural TB.

Authors:  L El Fenniri; Z Toossi; H Aung; G El Iraki; J Bourkkadi; J Benamor; A Laskri; N Berrada; A Benjouad; H Mayanja-Kizza; M R Betts; R El Aouad; D H Canaday
Journal:  Tuberculosis (Edinb)       Date:  2011-04-02       Impact factor: 3.131

3.  Induction of serine protease inhibitor 9 by Mycobacterium tuberculosis inhibits apoptosis and promotes survival of infected macrophages.

Authors:  Zahra Toossi; Mianda Wu; Roxana Rojas; Barbara Kalsdorf; Htin Aung; Christina S Hirsch; Jessica Walrath; Angela Wolbink; Marieke van Ham; Richard F Silver
Journal:  J Infect Dis       Date:  2011-11-16       Impact factor: 5.226

4.  Proteomic and bioinformatics profile of paired human alveolar macrophages and peripheral blood monocytes.

Authors:  Sara E Tomechko; Kathleen C Lundberg; Jessica Jarvela; Gurkan Bebek; Nicole G Chesnokov; Daniela Schlatzer; Rob M Ewing; W Henry Boom; Mark R Chance; Richard F Silver
Journal:  Proteomics       Date:  2015-11       Impact factor: 3.984

5.  Mycobacterium tuberculosis-Induced Bronchoalveolar Lavage Gene Expression Signature in Latent Tuberculosis Infection Is Dominated by Pleiotropic Effects of CD4+ T Cell-Dependent IFN-γ Production despite the Presence of Polyfunctional T Cells within the Airways.

Authors:  Jessica Jarvela; Michelle Moyer; Patrick Leahy; Tracey Bonfield; David Fletcher; Wambura N Mkono; Htin Aung; David H Canaday; Jean-Eudes Dazard; Richard F Silver
Journal:  J Immunol       Date:  2019-09-20       Impact factor: 5.422

6.  Human alveolar macrophage gene responses to Mycobacterium tuberculosis strains H37Ra and H37Rv.

Authors:  Richard F Silver; Jessica Walrath; Hung Lee; Bruce A Jacobson; Heidi Horton; Michael R Bowman; Karl Nocka; Joseph P Sypek
Journal:  Am J Respir Cell Mol Biol       Date:  2008-09-11       Impact factor: 6.914

7.  Pulmonary responses to pathogen-specific antigens in latent Mycobacterium tuberculosis infection.

Authors:  Jessica R Jarvela; Lori Tuscano; Hung Lee; Richard F Silver
Journal:  Tuberculosis (Edinb)       Date:  2015-12-08       Impact factor: 3.131

8.  CXCR3 directs antigen-specific effector CD4+ T cell migration to the lung during parainfluenza virus infection.

Authors:  Jacob E Kohlmeier; Tres Cookenham; Shannon C Miller; Alan D Roberts; Jan P Christensen; Allan R Thomsen; David L Woodland
Journal:  J Immunol       Date:  2009-09-04       Impact factor: 5.422

9.  Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response.

Authors:  Thomas J Scriba; Barbara Kalsdorf; Deborah-Ann Abrahams; Fatima Isaacs; Jessica Hofmeister; Gillian Black; Hisham Y Hassan; Robert J Wilkinson; Gerhard Walzl; Sebastian J Gelderbloem; Hassan Mahomed; Gregory D Hussey; Willem A Hanekom
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

10.  HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria.

Authors:  Barbara Kalsdorf; Thomas J Scriba; Kathryn Wood; Cheryl L Day; Keertan Dheda; Rodney Dawson; Willem A Hanekom; Christoph Lange; Robert J Wilkinson
Journal:  Am J Respir Crit Care Med       Date:  2009-09-24       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.